A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections

Chemotherapy

Volumn 56, Issue 5, 2010, Pages 378-385

  Wang, Jin ^a   Xiao, Yonghong ^a   Huang, Wenxiang ^b   Xu, Nan ^c   Bai, Chunxue ^d   Xiu, Qingyu ^e   Mei, Changlin ^f   Zheng, Qingshan ^g  

^a PEKING UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g Anhui Provincial Center for Drug Clinical Evaluation   (China)

Author keywords

Acute exacerbation of chronic bronchitis; Acute pyelonephritis; Antofloxacin hydrochloride; Levofloxacin hydrochloride

Indexed keywords

ANTOFLOXACIN HYDROCHLORIDE; LEVOFLOXACIN; PLACEBO; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANOREXIA; ARTICLE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INSOMNIA; LEUKOPENIA; LIVER FUNCTION TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT;

ACUTE DISEASE; ADULT; AGED; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PYELONEPHRITIS;

EID: 77957745998     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317581     Document Type: Article

References (19)

1. Ye H, Wu JM, Yang YS, Chen KX, Ji RY: Antibacterial activities of the derivatives YH54 and YH57 of levofloxacin in vitro. Chin Pharmacol Bull 2002; 18: 112-113. (Pubitemid 34259510)
2. Xiao YH, Li Y, Liu J, Zhong W, Yang WW: Primary study of antofloxacin breakpoint with disc diffusion sensitive test. Chin J Clin Pharmacol Ther 2010, in press.
3. Xiao YH, Lu Y, Kang ZS, Zhang M, Liu Y, Zhang M, Li TY: Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008; 29: 167-172. (Pubitemid 351722161)
4. Xiao YH, Lu Y, Kang ZS, Hou F, Wang S, Li TY, Liu Y, Xia YH: Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 2008; 46: 172-179. (Pubitemid 351493987)
5. Chen HZ: Practice of Internal Medicine, ed 15. Beijing, People's Medical Publishing House, 2001.
6. Xiao XM, Xiao YH: Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection. Acta Pharmacol Sin 2008; 29: 1253-1260.
7. Ball P, Wilson RM, Andell L, Brown J, Henkel T: Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: A randomized, double-blind comparison with tro vafloxacin. J Chemother 2001; 13: 288-298. (Pubitemid 32575142)
8. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, Sagnier PP: Shortterm and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute bacterial exacerbations of chronic bronchitis. Chest 2004; 125: 953-964. (Pubitemid 38367286)
9. Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R: Levofloxacin versus cefuroxime axetil in the treatment of acute bacterial exacerbations of chronic bronchitis: Results of a randomized, double-blind study. J Antimicrob Chemother 1999; 43: 529-539. (Pubitemid 29182303)
10. Soler M, Lode H, Baldwin R, Levine JH, Schruers AJ, van Noord JA, Maesen MP, Zehrer M: Randomized double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic bronchitis. Euro J Clin Microbiol Infect Dis 2003; 22: 144-150. (Pubitemid 36461363)
11. Li JT, Yang M, Weinstein AJ: Surveillance of bacterial resistance in China (1998-1999) (in Chinese). Natl Med J Chin 2001; 81: 8-16.
12. Cox CE, Marbury TC, Pittman WG, Brown JL, Auerbach SM, Fox BC, Yang JY: A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 2002; 24: 223-236. (Pubitemid 34208417)
13. Talan DA, Stamm WE, Hooton TM, Moran GL, Burke T, Iravani A, Reuning-Scherer J, Church DA: Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: A randomized trial. JAMA 2000; 283: 1583-1590. (Pubitemid 30161514)
14. Barman B, Four JA, Wiseman LR: Moxifloxacin. Drugs 1999; 57: 363-373.
15. Joseph BJ, Douglas F: The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817.
16. Yamagchi H, Kawai H, Matsumoto T, Yokoyama H, Nakayasu T, Komiya M, Shimada J: Post-marketing surveillance of the safety of levofloxacin in Japan. Chemotherapy 2007; 53: 85-103. (Pubitemid 46377215)
17. Koksal F, Ak K, Kucukbasmaci O, Samasti M: Prevalence and antimicrobial resistance patterns of extended-spectrum β -lactamaseproducing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital. Chemotherapy 2009; 55: 293-297.
18. Stahlmann R: Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269-277. (Pubitemid 34615518)
19. Lv Y, Xiao YH, Liu Y, Xia YH, Li TY: Tolerance of antofloxacin hydrochloride after ascending single oral dose administration in health male volunteers. Chin J Clin Pharmacol 2008; 24: 17-21. (Pubitemid 351493987)